PriceTargets.com logo

Clearside Biomedical - CLSD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.75
  • Forecasted Upside: 276.98%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.26 As of 04/25/2024 01:00 AM ET
▼ -0.08 (-5.97%)

This chart shows the closing price for CLSD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Clearside Biomedical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLSD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLSD

Analyst Price Target is $4.75
▲ +276.98% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Clearside Biomedical in the last 3 months. The average price target is $4.75, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 276.98% upside from the last price of $1.26.

This chart shows the closing price for CLSD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Clearside Biomedical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
3/13/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00N/A
3/13/2024WedbushReiterated RatingOutperform ➝ Outperform$5.00 ➝ $4.00Low
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
11/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
8/15/2023WedbushReiterated RatingOutperform$5.00Low
8/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$5.00Low
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$4.00Low
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
4/28/2023500.comReiterated RatingReiteratesLow
4/20/2023Needham & Company LLCReiterated RatingBuy$4.00Low
4/19/2023HC WainwrightReiterated RatingBuy$6.00Low
3/10/2023HC WainwrightReiterated RatingBuy$6.00Low
3/10/2023JMP SecuritiesLower TargetMarket Outperform$7.00 ➝ $6.00Low
3/10/2023Needham & Company LLCLower TargetBuy$5.00 ➝ $4.00Low
2/13/2023JMP SecuritiesReiterated RatingMarket Outperform$7.00Low
2/3/2023Needham & Company LLCReiterated RatingBuy$5.00Low
11/10/2022Needham & Company LLCUpgradeHold ➝ Buy$5.00Low
11/10/2022HC WainwrightBoost TargetBuy$5.00 ➝ $6.00Low
11/9/2022Stifel NicolausUpgradeHold ➝ Buy$8.00Low
8/10/2022HC WainwrightLower TargetBuy$10.00 ➝ $5.00Low
3/11/2022WedbushReiterated RatingOutperform$9.00Low
3/11/2022JMP SecuritiesLower TargetMarket Outperform$11.00 ➝ $10.00High
12/22/2021HC WainwrightReiterated RatingBuy$10.00Low
12/15/2021WedbushReiterated RatingOutperformHigh
11/23/2021JMP SecuritiesReiterated RatingBuy$11.00High
10/13/2021JMP SecuritiesReiterated RatingBuy$10.00Low
10/4/2021JMP SecuritiesReiterated RatingBuy$10.00High
9/22/2021HC WainwrightReiterated RatingBuy$10.00Medium
9/21/2021JMP SecuritiesReiterated RatingBuy$10.00Low
9/21/2021WedbushReiterated RatingBuy$18.00Low
9/10/2021WedbushReiterated RatingBuy$18.00High
7/29/2021HC WainwrightInitiated CoverageBuy$10.00Medium
6/18/2021Roth CapitalBoost TargetBuy$9.00 ➝ $15.00Medium
6/17/2021WedbushBoost TargetPositive ➝ Outperform$6.00 ➝ $18.00High
6/15/2021JMP SecuritiesBoost TargetMarket Outperform$8.00 ➝ $9.00High
5/18/2021WedbushReiterated RatingBuy$6.00Medium
5/18/2021Roth CapitalBoost TargetBuy$8.00 ➝ $9.00Medium
5/3/2021WedbushReiterated RatingBuy$6.00Low
2/19/2021WedbushReiterated RatingBuy$6.00Medium
2/10/2021WedbushReiterated RatingBuy$5.00Low
11/11/2020Needham & Company LLCReiterated RatingHoldHigh
6/18/2020WedbushReiterated RatingBuy$6.00Medium
6/4/2020Janney Montgomery ScottReiterated RatingBuy ➝ Market Perform$5.00High
5/13/2020Roth CapitalInitiated CoverageBuy$8.00High
4/28/2020WedbushReiterated RatingBuy$6.00High
4/28/2020Needham & Company LLCReiterated RatingHoldMedium
3/12/2020WedbushReiterated RatingBuy$6.00High
2/11/2020WedbushReiterated RatingBuy$5.00High
1/27/2020WedbushBoost TargetOutperform$3.00 ➝ $5.00High
12/18/2019WedbushReiterated RatingBuy$3.00High
12/17/2019JMP SecuritiesReiterated RatingBuy$4.00High
11/24/2019WedbushReiterated RatingBuy$3.00Low
10/31/2019Needham & Company LLCReiterated RatingHoldMedium
10/21/2019WedbushReiterated RatingBuy$3.00High
8/22/2019JMP SecuritiesSet TargetBuy$4.00 ➝ $3.00High
8/13/2019LaidlawDowngradeBuy ➝ HoldLow
8/12/2019JMP SecuritiesLower TargetOutperform$12.00 ➝ $4.00Low
8/9/2019Needham & Company LLCDowngradeBuy ➝ HoldN/A
8/6/2019WedbushReiterated RatingBuy$4.00High
7/29/2019WedbushReiterated RatingOutperform$4.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Clearside Biomedical logo
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $1.26
Low: $1.26
High: $1.34

50 Day Range

MA: $1.45
Low: $1.15
High: $2.02

52 Week Range

Now: $1.26
Low: $0.65
High: $2.12

Volume

135,231 shs

Average Volume

287,330 shs

Market Capitalization

$94.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Clearside Biomedical?

The following Wall Street sell-side analysts have issued stock ratings on Clearside Biomedical in the last year: 500.com Limited, HC Wainwright, JMP Securities, Needham & Company LLC, StockNews.com, and Wedbush.
View the latest analyst ratings for CLSD.

What is the current price target for Clearside Biomedical?

4 Wall Street analysts have set twelve-month price targets for Clearside Biomedical in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 277.0%. HC Wainwright has the highest price target set, predicting CLSD will reach $6.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $4.00 for Clearside Biomedical in the next year.
View the latest price targets for CLSD.

What is the current consensus analyst rating for Clearside Biomedical?

Clearside Biomedical currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLSD will outperform the market and that investors should add to their positions of Clearside Biomedical.
View the latest ratings for CLSD.

What other companies compete with Clearside Biomedical?

Other companies that are similar to Clearside Biomedical include Barinthus Biotherapeutics, Eliem Therapeutics, Cellectar Biosciences, FibroGen and Vaccitech. Learn More about companies similar to Clearside Biomedical.

How do I contact Clearside Biomedical's investor relations team?

Clearside Biomedical's physical mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company's listed phone number is (678) 270-3631 and its investor relations email address is [email protected]. The official website for Clearside Biomedical is www.clearsidebio.com. Learn More about contacing Clearside Biomedical investor relations.